Hikma Pharmaceuticals PLC (LON:HIK)
London
· Delayed Price · Currency is GBP · Price in GBX 1,191.00
-18.00 (-1.49%)
At close: Mar 9, 2026
Hikma Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 3,349 | 3,127 | 2,875 | 2,517 | 2,553 | Upgrade
|
| Revenue Growth (YoY) | 7.10% | 8.77% | 14.22% | -1.41% | 9.06% | Upgrade
|
| Cost of Revenue | 1,908 | 1,712 | 1,468 | 1,252 | 1,252 | Upgrade
|
| Gross Profit | 1,441 | 1,415 | 1,407 | 1,265 | 1,301 | Upgrade
|
| Selling, General & Admin | 666 | 662 | 632 | 601 | 561 | Upgrade
|
| Research & Development | 151 | 141 | 149 | 144 | 143 | Upgrade
|
| Other Operating Expenses | -1 | 4 | 1 | 22 | 36 | Upgrade
|
| Operating Expenses | 816 | 807 | 782 | 767 | 740 | Upgrade
|
| Operating Income | 625 | 608 | 625 | 498 | 561 | Upgrade
|
| Interest Expense | -106 | -75 | -73 | -59 | -43 | Upgrade
|
| Interest & Investment Income | 11 | 8 | 7 | 3 | 1 | Upgrade
|
| Earnings From Equity Investments | - | 1 | - | - | 1 | Upgrade
|
| Currency Exchange Gain (Loss) | - | -21 | -9 | -7 | - | Upgrade
|
| Other Non Operating Income (Expenses) | - | -13 | -14 | -11 | -13 | Upgrade
|
| EBT Excluding Unusual Items | 530 | 508 | 536 | 424 | 507 | Upgrade
|
| Merger & Restructuring Charges | -5 | -9 | - | -41 | - | Upgrade
|
| Gain (Loss) on Sale of Investments | 1 | 1 | 2 | -2 | - | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | 12 | -1 | Upgrade
|
| Asset Writedown | -26 | 29 | -85 | -182 | 22 | Upgrade
|
| Legal Settlements | -72 | - | -129 | - | - | Upgrade
|
| Other Unusual Items | 77 | -74 | -43 | 22 | 16 | Upgrade
|
| Pretax Income | 519 | 455 | 281 | 233 | 544 | Upgrade
|
| Income Tax Expense | 112 | 93 | 89 | 42 | 124 | Upgrade
|
| Earnings From Continuing Operations | 407 | 362 | 192 | 191 | 420 | Upgrade
|
| Minority Interest in Earnings | -5 | -3 | -2 | -3 | 1 | Upgrade
|
| Net Income | 402 | 359 | 190 | 188 | 421 | Upgrade
|
| Net Income to Common | 402 | 359 | 190 | 188 | 421 | Upgrade
|
| Net Income Growth | 11.98% | 88.95% | 1.06% | -55.34% | -2.32% | Upgrade
|
| Shares Outstanding (Basic) | 221 | 221 | 221 | 224 | 231 | Upgrade
|
| Shares Outstanding (Diluted) | 223 | 223 | 222 | 225 | 233 | Upgrade
|
| Shares Change (YoY) | -0.36% | 0.51% | -1.13% | -3.47% | -2.10% | Upgrade
|
| EPS (Basic) | 1.82 | 1.62 | 0.86 | 0.84 | 1.82 | Upgrade
|
| EPS (Diluted) | 1.81 | 1.61 | 0.85 | 0.84 | 1.81 | Upgrade
|
| EPS Growth | 12.42% | 89.41% | 1.19% | -53.51% | -0.22% | Upgrade
|
| Free Cash Flow | 239 | 399 | 439 | 392 | 493 | Upgrade
|
| Free Cash Flow Per Share | 1.07 | 1.78 | 1.97 | 1.74 | 2.12 | Upgrade
|
| Dividend Per Share | 0.840 | 0.800 | 0.720 | 0.560 | 0.540 | Upgrade
|
| Dividend Growth | 5.00% | 11.11% | 28.57% | 3.70% | 8.00% | Upgrade
|
| Gross Margin | 43.03% | 45.25% | 48.94% | 50.26% | 50.96% | Upgrade
|
| Operating Margin | 18.66% | 19.44% | 21.74% | 19.79% | 21.97% | Upgrade
|
| Profit Margin | 12.00% | 11.48% | 6.61% | 7.47% | 16.49% | Upgrade
|
| Free Cash Flow Margin | 7.14% | 12.76% | 15.27% | 15.57% | 19.31% | Upgrade
|
| EBITDA | 819 | 787 | 797 | 670 | 718 | Upgrade
|
| EBITDA Margin | 24.45% | 25.17% | 27.72% | 26.62% | 28.12% | Upgrade
|
| D&A For EBITDA | 194 | 179 | 172 | 172 | 157 | Upgrade
|
| EBIT | 625 | 608 | 625 | 498 | 561 | Upgrade
|
| EBIT Margin | 18.66% | 19.44% | 21.74% | 19.79% | 21.97% | Upgrade
|
| Effective Tax Rate | 21.58% | 20.44% | 31.67% | 18.03% | 22.79% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.